Reimbursement

Medical device reimbursement in Czechia and Slovakia

Choosing the reimbursement pathway determines price, volume and speed of market entry. We build the strategy, assemble the dossier, model the budget impact and lead negotiations with SÚKL, health insurance funds and medical societies.

Separately billed material (ZUM)Prescription devicesProcedure reimbursement

Where the difference is made

Reimbursement strategy belongs in development

The most expensive mistake in device reimbursement is not a rejected application. It is a device that obtained its CE certificate before anyone checked whether a reimbursement pathway exists for it in the Czech system — and what evidence that pathway demands.

Intended purpose, target population and comparator define not only the clinical evaluation but also what the device will be compared against in the reimbursement procedure. When those two drift apart, the evidence is missing exactly where it is needed.

  • Pathway analysis and a recommendation you can act on
  • Target population and comparator definition
  • Achievable reimbursement estimate and volume sensitivity
  • Full dossier including the economic section
  • Budget impact model for Czechia, MER for Slovakia
  • Medical society and KOL engagement
  • Submission, defence and responses to authority queries
  • Maintenance after listing, including categorisation tree changes

FAQ

Questions we hear most

Answers reflect the rules and decision practice as of September 2026.

What is ZUM?

Separately billed material — a device consumed during a health service and invoiced to the insurance fund separately from the procedure itself. Typical examples are implants, catheters and stents used inside a healthcare facility.

It differs from a prescription device in the set of decision-makers, the evidence required and the time to reimbursement.

Do we need a budget impact analysis?

For any material submission, yes. The payer needs to know how many patients are affected, the expected uptake over time and which costs the device replaces or adds.

A well-built BIA is often an argument about the level of reimbursement, not only about reimbursement as such.

What if no suitable procedure exists?

Then a new procedure has to be created or an existing one amended in the List of Health Services. This requires a medical society and a cost calculation, and it is a longer route. We usually start by mapping whether an existing procedure can be extended.

Working on a specific device?

Send us the intended purpose, class and project stage. We will come back with a proposed pathway and the evidence it requires.

Managing DirectorMartin Kolekmartin.kolek@ceeor.com+420 728 411 042
Regulatory AffairsIvana Kubátováivana.kubatova@ceeor.com+420 602 345 190